72 Chapter 5 Table 2. Continued Preoperative characteristics Total (n = 297) No implant loss (n = 262) Implant loss (n = 35) p-value* Missing 3 (1.0) 2 (0.8) 1 (2.9) Axillary dissection 12 (4.0) 10 (3.8) 2 (5.7) 0.637 Missing 4 (1.3) 3 (1.1) 1 (2.9) Type of reconstruction 0.002 Prosthesis 60 (20.2) 46 (17.6) 14 (40.0) Tissue expander 237 (79.8) 216 (82.4) 21 (60.0) Prosthesis size 413 (175–750) 375 (175–750) 495 (240–680) 0.143 Tissue expander size 400 (200–800) 400 (200–800) 500 (300–800) 0.005 Perioperative filling 150 (40–400) 150 (40–400) 200 (100–400) 0.008 First filling day 27 (11–193) Location 1.000 Prepectoral 4 (1.3) 4 (1.5) 0 (0) Subpectoral 281 (94.6) 249 (95.0) 32 (91.4) Missing 12 (4.0) 9 (3.4) 3 (8.6) Radiotherapy 0.747 No 227 (76.4) 200 (76.3) 27 (77.1) Yes (postoperative) 59 (19.9) 53 (20.2) 6 (17.1) Preceding 11 (3.7) 9 (3.4) 2 (5.7) Hormonal therapy 118 (39.7) 106 (40.5) 12 (34.3) 0.483 Bilateral 145 (48.8) 124 (47.3) 21 (60.0) 0.159 Significant p-values are denoted in italic. ASA: American Association of Anesthesiologists; BMI: Body mass index; DCIS: Ductal carcinoma in situ. Among the implant-based breast reconstructions with implant loss, the following additional complications were significantly more observed compared with those without implant loss: SSI (54.3% vs 13%, p < 0.001), wound dehiscence (22.9% vs 2.7%, p < 0.001), necrosis in general (62.9% vs 3.8%, p < 0.001), and necrosis of the nipple (40% vs 2.7%, p < 0.001). A comparison of all postoperative outcomes between these two groups is presented in Table 3.
RkJQdWJsaXNoZXIy MTk4NDMw